The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Exon 7 Deletion in the bcr-abl Gene Is Frequent in Chronic Myeloid Leukemia Patients and Is Not Correlated with Resistance against Imatinib
Abstract
Chronic myeloid leukemia (CML) patients treated with imatinib develop frequent resistance generally due to a point mutation. Recently, large rearrangements of abl sequence have also been described. In this study, we focused on the complete deletion of exon 7. We screened for bcr-abldelexon7 in 63 resistant patients by high-resolution melting (HRM) analysis and direct sequencing. Moreover, we analyzed expression of abldelexon7 and bcr-abldelexon7 in 17 CML patients at diagnosis, 32 patients at resistance, and 20 negative controls by quantitative PCR or fragment length analysis. bcr-abldelexon7 was detected on 34 (54%) among 63 resistant patients by HRM, showing an increase in the sensitivity of screening, because only 3.2% could be detected by direct sequencing. This deletion was not associated with a point mutation (P = 0.3362). In addition, abldelexon7 was found in all tested samples with the same pattern of expression, suggesting an alternative splicing mechanism. In the bcr-abl component, there was no statistical difference between CML patients at diagnosis and resistant patients (P = 0.2815) as regarding bcr-abldelexon7 proportion, thus arguing against involvement of deletion in resistance. Moreover, among two patients harboring bcr-abldelexon7 at diagnosis, one experienced a complete disappearance of this transcript, and the other decreased >75% at resistance. In conclusion, bcr-abldelexon7 is frequently observed in CML patients when using sensitive techniques. It seems to be the result of an alternative splicing mechanism and to be independent from the occurrence of resistance. Mol Cancer Ther; 9(11); 3083–9. ©2010 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies showed that aberrant RNA splicing in BCR-ABL variants (BCR-ABL35INS) has been associated with poor response to TKI treatment (Imatinib) [86–88].”
From GOLDEN fusion: a graph-oriented learning with domain-embedding network fusion for generating super gene sets in functional genomics (2026) · cites this paper as [88]
Citations
Cites
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches
Chen, M., & Manley, J. L. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2777 · Cited by 1,284
Predictive Identification of Exonic Splicing Enhancers in Human Genes
Fairbrother, W. G., Yeh, R.-F., Sharp, P. A., & Burge, C. B. (2002) · Science · doi:10.1126/science.1073774 · Cited by 1,036
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Müller, M. C., Radich, J. P., Rudoltz, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.38 · Cited by 856
Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 643
Aberrant and Alternative Splicing in Cancer
Venables, J. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1910 · Cited by 634
Cited by
Aberrant RNA Splicing in Cancer and Drug Resistance
Wang, B.-D., & Lee, N. (2018) · Cancers · doi:10.3390/cancers10110458 · Cited by 182
Deininger, M. W., Hodgson, J., Shah, N. P., Cortes, J. E., Kim, D., Nicolini, F. E., Talpaz, M., Baccarani, M., Müller, M. C., Li, J., et al. (2015) · Blood · doi:10.1182/blood-2015-08-660977 · Cited by 110
Cavelier, L. B., Ameur, A., Häggqvist, S., Höijer, I., Cahill, N., Olsson‐Strömberg, U., & Hermanson, M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1046-y · Cited by 55
“These results corroborate previous findings that propose alternative splicing as a common mechanism among CML patients undergoing TKI treatment [14,17].”
ResultO’Hare, T., Zabriskie, M. S., Eide, C. A., Agarwal, A., Adrian, L. T., You, H., Corbin, A. S., Yang, F., Press, R. D., Rivera, V. M., et al. (2011) · Blood · doi:10.1182/blood-2011-05-349191 · Cited by 48
Tadesse, F., Asres, G., Abubeker, A., Gebremedhin, A., & Radich, J. P. (2021) · JCO Global Oncology · doi:10.1200/go.21.00058 · Cited by 22
“Alternative splicing in BCRABL, including BCR-ABL and exon 7 deletion, has been implicated as the mechanism of TKI resistance,(14,30,34,37-42) although the contribution of this mutation to TKI resistance is inconsistent.(35,36,43,44)”
Background
Metadata
- Authors
- Gaillard, J.-B., Arnould, C., Bravo, S., Donadio, D., Exbrayat, C., Jourdan, E., Reboul, D., Chiesa, J., & Lavabre-Bertrand, T.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Authors' Affiliations: Departments of 1Clinical Cytology and Cytogenetics and 2Hematology, Nîmes University Hospital, Nîmes, France; 3UMR-CNRS 5247, Montpellier, France; and 4Hématologie et oncologie médicale, Clinique du Parc, Castelnau Le Lez, France
- Venue
- Molecular Cancer Therapeutics
- Published
- 2010-11-01
- Volume
- 9
- Issue
- 11
- Pages
- 3083-3089
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2151186464
- Cited by
- 23
- References
- 35
- Citations by year
- 2026: 1 · 2024: 1 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 2 · 2014: 1 · 2013: 1
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- chronic myeloid leukemia, BCR-ABL, exon 7 deletion, imatinib resistance, alternative splicing, point mutations, high-resolution melting analysis, transcript expression
- MeSH terms
- Imatinib Mesylate, Antineoplastic Agents, Benzamides, DNA Mutational Analysis, Exons, Gene Frequency, Genetic Testing, Humans, Nucleic Acid Denaturation, Piperazines, Pyrimidines, Temperature, Cohort Studies, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Gene Deletion, Drug Resistance, Neoplasm, Protein Isoforms, Genetic Association Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exon 7 Deletion in the bcr-abl Gene Is Frequent in Chronic Myeloid Leukemia Patients and Is Not Correlated with Resistance against Imatinib. https://app.cochat.ai/papers/10.1158/1535-7163.mct-10-0595
- The paper
- Gaillard, J.-B., Arnould, C., Bravo, S., Donadio, D., Exbrayat, C., Jourdan, E., Reboul, D., Chiesa, J., & Lavabre-Bertrand, T. (2010). Exon 7 Deletion in the bcr-abl Gene Is Frequent in Chronic Myeloid Leukemia Patients and Is Not Correlated with Resistance against Imatinib. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-10-0595
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.